Get started
AMICUS THERAPEUTICS INC.AMICUS THERAPEUTICS INC.AMICUS THERAPEUTICS INC.

AMICUS THERAPEUTICS INC.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Forecast Seasonals

AM6 chart


Full chart

AM6 upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪2.73 B‬ EUR
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.30 EUR
Net income (FY)
‪−137.34 M‬ EUR
Revenue (FY)
‪361.82 M‬ EUR
Shares float
‪291.26 M‬
Beta (1Y)
0.19

About Amicus Therapeutics, Inc.


Sector
Health Technology
CEO
Bradley Lewis Campbell
Headquarters
Princeton
Website
amicusrx.com
Founded
2002
FIGI
BBG000F0TVG5
Amicus Therapeutics, Inc. operates as a biotechnology company. The firm focuses on discovering, developing and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio. The company was founded by John Francis Crowley on February 4, 2002 and is headquartered in Princeton, NJ.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

AM6 news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange AMICUS THERAPEUTICS INC. stocks are traded under the ticker AM6.
We've gathered analysts' opinions on AMICUS THERAPEUTICS INC. future price: according to them, AM6 price has a max estimate of 20.29 EUR and a min estimate of 11.59 EUR. Watch AM6 chart and read a more detailed AMICUS THERAPEUTICS INC. stock forecast: see what analysts think of AMICUS THERAPEUTICS INC. and suggest that you do with its stocks.
AM6 reached its all-time high on Dec 23, 2020 with the price of 20.40 EUR, and its all-time low was 1.30 EUR and was reached on Apr 17, 2014. View more price dynamics on AM6 chart.
See other stocks reaching their highest and lowest prices.
Yes, you can track AMICUS THERAPEUTICS INC. financials in yearly and quarterly reports right on TradingView.
AMICUS THERAPEUTICS INC. is going to release the next earnings report on Feb 26, 2025. Keep track of upcoming events with our Earnings Calendar.
AM6 earnings for the last quarter are −0.02 EUR per share, whereas the estimation was 0.00 EUR resulting in a ‪−1.79 K‬% surprise. The estimated earnings for the next quarter are 0.02 EUR per share. See more details about AMICUS THERAPEUTICS INC. earnings.
AMICUS THERAPEUTICS INC. revenue for the last quarter amounts to ‪127.10 M‬ EUR, despite the estimated figure of ‪121.18 M‬ EUR. In the next quarter, revenue is expected to reach ‪142.36 M‬ EUR.
AM6 net income for the last quarter is ‪−6.04 M‬ EUR, while the quarter before that showed ‪−14.65 M‬ EUR of net income which accounts for 58.76% change. Track more AMICUS THERAPEUTICS INC. financial stats to get the full picture.
No, AM6 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jan 7, 2025, the company has 517.00 employees. See our rating of the largest employees — is AMICUS THERAPEUTICS INC. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. AMICUS THERAPEUTICS INC. EBITDA is ‪20.74 M‬ EUR, and current EBITDA margin is −16.43%. See more stats in AMICUS THERAPEUTICS INC. financial statements.
Like other stocks, AM6 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade AMICUS THERAPEUTICS INC. stock right from TradingView charts — choose your broker and connect to your account.